2-arachidonoylglycerol

2-arachidonoylglycerol is a lipid of Glycerolipids (GL) class. 2-arachidonoylglycerol is associated with abnormalities such as Atherosclerosis, Heart Diseases, Inflammatory disorder, Colitis and Peripheral Neuropathy. The involved functions are known as Immunoreactivity, inhibitors, Stimulus, Esthesia and Signal Transduction. 2-arachidonoylglycerol often locates in Back, Presynaptic Terminals, Brain region, Blood and Body tissue. The associated genes with 2-arachidonoylglycerol are ADRBK1 gene, Homologous Gene, MGLL gene, PLA2G4A gene and peptide V. The related lipids are oleoylethanolamide, Lipopolysaccharides, Promega, stearic acid and 1-stearoyl-2-arachidonoylglycerol. The related experimental models are Knock-out.

Cross Reference

Introduction

To understand associated biological information of 2-arachidonoylglycerol, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with 2-arachidonoylglycerol?

2-arachidonoylglycerol is suspected in Atherosclerosis, Heart Diseases, Sweet's Syndrome, Colitis, Dehydration, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 2-arachidonoylglycerol

MeSH term MeSH ID Detail
Ganglion Cysts D045888 1 associated lipids
Fetal Nutrition Disorders D048070 1 associated lipids
Neuromyelitis Optica D009471 2 associated lipids
Acute Pain D059787 3 associated lipids
Head Injuries, Closed D016489 5 associated lipids
Brain Concussion D001924 5 associated lipids
Fragile X Syndrome D005600 5 associated lipids
Cholangiocarcinoma D018281 7 associated lipids
Morphine Dependence D009021 9 associated lipids
Hepatic Encephalopathy D006501 9 associated lipids
Per page 10 20 50 100 | Total 51

PubChem Associated disorders and diseases

What pathways are associated with 2-arachidonoylglycerol

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with 2-arachidonoylglycerol?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with 2-arachidonoylglycerol?

Knock-out

Knock-out are used in the study 'Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice.' (Walentiny DM et al., 2015), Knock-out are used in the study 'Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12).' (Navia-Paldanius D et al., 2012) and Knock-out are used in the study 'Metabolic Interplay between Astrocytes and Neurons Regulates Endocannabinoid Action.' (Viader A et al., 2015).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with 2-arachidonoylglycerol

Download all related citations
Per page 10 20 50 100 | Total 1060
Authors Title Published Journal PubMed Link
Hayase T et al. Persistent anxiogenic effects of a single or repeated doses of cocaine and methamphetamine: interactions with endogenous cannabinoid receptor ligands. 2005 Behav Pharmacol pmid:16148444
Gokoh M et al. 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces rapid actin polymerization in HL-60 cells differentiated into macrophage-like cells. 2005 Biochem. J. pmid:15456404
Sancho R et al. Mechanisms of HIV-1 inhibition by the lipid mediator N-arachidonoyldopamine. 2005 J. Immunol. pmid:16148147
Harada N et al. Effects of cannabinoids on colonic muscle contractility and tension in guinea pigs. 2005 J Nippon Med Sch pmid:15834207
Oka S et al. Evidence for the involvement of the cannabinoid CB2 receptor and its endogenous ligand 2-arachidonoylglycerol in 12-O-tetradecanoylphorbol-13-acetate-induced acute inflammation in mouse ear. 2005 J. Biol. Chem. pmid:15749716
Kishimoto S et al. Endogenous cannabinoid receptor ligand induces the migration of human natural killer cells. 2005 J. Biochem. pmid:15749836
Kaplan BL et al. 2-Arachidonoyl-glycerol suppresses interferon-gamma production in phorbol ester/ionomycin-activated mouse splenocytes independent of CB1 or CB2. 2005 J. Leukoc. Biol. pmid:15774549
Lauckner JE et al. The cannabinoid agonist WIN55,212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins. 2005 Proc. Natl. Acad. Sci. U.S.A. pmid:16365309
Hill MN et al. Chronic corticosterone treatment increases the endocannabinoid 2-arachidonylglycerol in the rat amygdala. 2005 Eur. J. Pharmacol. pmid:16324692
Gokoh M et al. 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, enhances the adhesion of HL-60 cells differentiated into macrophage-like cells and human peripheral blood monocytes. 2005 FEBS Lett. pmid:16288744
Iturralde M et al. Characterization of the lipolytic pathways that mediate free fatty acid release during Fas/CD95-induced apoptosis. 2005 Apoptosis pmid:16215685
Engeli S et al. Activation of the peripheral endocannabinoid system in human obesity. 2005 Diabetes pmid:16186383
Safo PK and Regehr WG Endocannabinoids control the induction of cerebellar LTD. 2005 Neuron pmid:16301180
Alger BE Endocannabinoid identification in the brain: studies of breakdown lead to breakthrough, and there may be NO hope. 2005 Sci. STKE pmid:16278487
Ligresti A et al. Endocannabinoid metabolic pathways and enzymes. 2005 Curr Drug Targets CNS Neurol Disord pmid:16375679
Shoemaker JL et al. The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors. 2005 J. Pharmacol. Exp. Ther. pmid:15901805
Saario SM et al. Characterization of the sulfhydryl-sensitive site in the enzyme responsible for hydrolysis of 2-arachidonoyl-glycerol in rat cerebellar membranes. 2005 Chem. Biol. pmid:15975510
Di S et al. Activity-dependent release and actions of endocannabinoids in the rat hypothalamic supraoptic nucleus. 2005 J. Physiol. (Lond.) pmid:16239276
Cabranes A et al. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. 2005 Neurobiol. Dis. pmid:16242629
McPartland JM et al. Cannabimimetic effects of osteopathic manipulative treatment. 2005 J Am Osteopath Assoc pmid:16118355